Benzinga | Dec 21, 2021 06:51AM EST

Baird Maintains Neutral on Biogen, Lowers Price Target to $258

Baird analyst Brian Skorney maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers the price target from $296 to $258.